Source-grounded facts extracted from TANDEM DIABETES CARE INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mark Novara was terminated as Executive Vice President and Chief Commercial Officer at TANDEM DIABETES CARE INC.
“On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.”
TANDEM DIABETES CARE INC incurred convertible notes of $300.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing March 15, 2032.
“On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $35.0 million principal amount of Notes.”
TANDEM DIABETES CARE INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $300.0 million aggregate principal amount (effective 2026-02-27).
“On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $35.0 million principal amount of Notes. The Notes were issued in accordance with an indenture, dated February 27, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”
TANDEM DIABETES CARE INC: Amended and Restated Bylaws effective December 26, 2025, updating advance notice provisions, meeting cancellation authority, proxy card color rule, indemnification, notice provisions, voting standards, stockholder list requirement, and certain technical changes (effective 2025-12-26).
“On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).”
Jean-Claude Kyrillos was appointed as Chief Operating Officer at TANDEM DIABETES CARE INC.
“On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.”
TANDEM DIABETES CARE INC amended Amendment Number 1 with Unomedical a/s (effective 2024-05-10).
“On May 10, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Unomedical a/s, a Danish corporation and a subsidiary of the ConvaTec Group (“Unomedical”), entered into Amendment Number 1 (“Amendment 1”) to the Distributor Agreement, dated as of January 14, 2022, between the Company and Unomedical, under which Unomedical manufactures, tests, sterilizes and packs all of the infusion sets under the Company’s brands (the “Original Agreement”).”
TANDEM DIABETES CARE INC incurred convertible notes of $316.25 million aggregate principal amount with U.S. Bank Trust Company, National Association at 1.50% per year maturing March 15, 2029.
“On March 8, 2024, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $316.25 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $41.25 million principal amount of Notes.”
TANDEM DIABETES CARE INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $316.25 million aggregate principal amount (effective 2024-03-08).
“Indenture and Notes On March 8, 2024, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $316.25 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.